MIRM
- Mirum Pharmaceuticals, Inc.
()
Overview
Company Summary
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare liver diseases. The company's mission is to deliver innovative treatments that have the potential to transform the lives of patients and their families.
Mirum Pharmaceuticals primarily specializes in diseases that affect the liver and bile ducts, including cholestatic liver diseases. Cholestatic liver diseases are a group of rare genetic disorders that impair the flow of bile, leading to the accumulation of toxic substances in the liver. These conditions can cause severe liver damage, which can further result in various complications and impaired liver function.
The company's primary drug candidate is maralixibat, an investigational oral therapy. Maralixibat works by inhibiting the ileal bile acid transporter (IBAT) to increase bile acid excretion, thereby reducing the accumulation of toxic bile acids. By targeting the underlying mechanisms of cholestatic liver diseases, maralixibat has the potential to improve the health and quality of life for patients.
Mirum Pharmaceuticals aims to provide comprehensive support to patients and their families through various programs and resources. This includes assistance with diagnosis, treatment, and ongoing management of their liver disease. The company also collaborates with healthcare professionals, advocacy groups, and academic institutions to further advance the understanding and treatment of rare liver diseases.
Overall, Mirum Pharmaceuticals is dedicated to developing effective therapies for rare liver diseases and ensuring that patients have access to innovative treatments that can help them lead healthier lives.